BridgeMD
New treatment option for Multiple Sclerosis
Official title Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis
ClinicalTrials.gov ID: NCT07159789
What this study is testing
- What it's testing
- Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Signed informed consent.
- Age ≥ 18 years and less than 71 years.
- Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018).
- EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more.
- Neurologically stable with no change in symptom related medications or relapse for at least 30 days prior to screening.
You likely can't join if
- Know presence of other neurologic disorders, which in the opinion of the investigator could add to the patient's neurological disability within the...
- Evidence of clinically significant cardiovascular (including arrhythmias), psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or...
- Pregnant or breastfeeding or intending to become pregnant during the study.
- Any previous rTMS therapy for any indication.
- Presence of any contraindication to rTMS therapy such as but not limited to: CNS implanted devices, pacemaker.
- Any condition which in the opinion of the investigator will render the patient unsuitable to participate in the study.
See the full eligibility criteria
- Signed informed consent.
- Age ≥ 18 years and less than 71 years.
- Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018).
- EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more.
- Neurologically stable with no change in symptom related medications or relapse for at least 30 days prior to screening.
- Patients will be allowed to continue fampridine provided they started more than 30 days prior to screening. They will not be allowed to start fampridine, any stimulant (modafenil, methylphenidate etc) or symptomatic...
- No change in disease modifying therapy for at least 3 months prior to screening.
- Ability to perform T25FWT, the MSQoL 6MWT Ability and willingness, in the investigator's opinion, to comply with the study protocol.
- Know presence of other neurologic disorders, which in the opinion of the investigator could add to the patient's neurological disability within the timespan of the study.
- Evidence of clinically significant cardiovascular (including arrhythmias), psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the investigator's opinion, would preclude...
- Pregnant or breastfeeding or intending to become pregnant during the study.
- Any previous rTMS therapy for any indication.
- Presence of any contraindication to rTMS therapy such as but not limited to: CNS implanted devices, pacemaker.
- Any condition which in the opinion of the investigator will render the patient unsuitable to participate in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Gatineau, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Gatineau, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.